FDA and Lilly Discuss Retatrutide Jurisdiction and Compounding Pathway | Retatrutide News

The FDA and Eli Lilly are discussing jurisdictional issues concerning Retatrutide, a GLP-1 agonist. This may affect its regulatory pathway and market st...
Market News · October 23, 2026